TrialSignal
Clinical trial intelligence report
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06268327
Status
NOT_YET_RECRUITING
Phase
Phase 2/3
Sponsor
Assiut University
Executive brief
Investment-Ready Snapshot
This clinical trial aims to evaluate the efficacy and toxicity of adjuvant cisplatin and gemcitabine compared to capecitabine in patients with triple-negative breast cancer who have not achieved a pathological complete response after neoadjuvant chemotherapy. The study is sponsored by Assiut University and is set to begin recruiting in April 2024.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06268327
Indication
Breast Cancer
Modality
small molecule
Target
Triple-negative breast cancer
Intervention
Cisplatin injection and gemcitabine, Capecitabine tablets
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.